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Summary 
The importance of endogenous interleukin 1 (II.-1) in resistance to Pneumocystis  carinii infection 
was examined in a SCID mouse model. Naturally acquired pulmonary infection of P. carinii in 
SCID mice was completely  cleared by reconstitution of the infected mice with immunocompetent 
spleen cells. I1:1 activity in the lung homogenate supernatant of these mice increased significantly 
after reconstitution and returned to baseline level after the clearance of P. carinii.  Treatment of 
reconstituted SCID mice with 35F5, a monoclonal antibody against murine type I I1:1R. almost 
completely inhibited  the  clearance  of P.  carinii.  In  contrast,  treatment  with  control  rat 
immunoglobulin G had no detectable effect. Further study revealed  that for the complete clearance 
ofP. carinii, I1:1 must be present at the early stage of immune responses induced by reconstitution, 
since clearance could be blocked by a single injection of 35F5 into SCID mice at 2 d, but not 
at  either 8 or 13 d  postreconstitution. Furthermore, pulmonary recruitment of neutrophils, 
macrophages, and lymphocytes  was significantly inhibited in mice that received 35F5 treatment. 
These findings strongly suggest that, in reconstituted SCID mice, endogenous I1:1 is important 
in host resistance to P. carinii infection  and that I1:1 may function early in the host response 
possibly by the recruitment of inflammatory cells into the lungs. 
neumocystis  carinii pneumonia is a major cause of mor- 
idity and mortality in AIDS patients, whereas the pneu- 
monia rarely occurs in immunocompetent hosts (1). CD4 § 
T lymphocytes are essential both in resistance to and recovery 
from the disease (2-4). However, CD4 + cells on their own 
are unlikely to function directly as effector cells in P. carinii 
killing,  and mechanisms by which these cells function are 
unknown. On the basis of  limited in vitro and in vivo studies, 
we (5) and others (6,  7) have postulated that CD4 + cells 
may function in resistance to P. carinii by regulating interac- 
tions between cytokines and effector cells. 
II.-1 is an important cytokine that mediates inflammation 
and other host physiological responses to a variety of infec- 
tions (8), including acute bacterial infection (9-11). The high 
incidence of P. carinii pneumonia in AIDS patients  (1) and 
the significant reduction of II:1 secretion by human macro- 
phages infected with HIV-1 (12) suggest that this cytokine 
may be important in resistance to P. carinii infection. The de- 
velopment of a specific mAb against murine I1:1 type IR 
(35F5) has permitted examination of the importance of I1:1 
in vivo. The 35F5 prevents binding of both Iblc~ and I1:1~ 
to the type I receptor, and thus blocks a number of I1:l-de- 
pendent effects in mice (10, 11, 13-15). In studies described 
in this report, this antibody was used to investigate the im- 
portance of endogenous ID1 in host defenses against P. carinii 
infection in a SCID mouse model. SCID mice spontaneously 
develop detectable P. carinii infection at about 3-wk of age, 
and resistance against the infection can be adoptively trans- 
ferred by reconstitution of the animals with spleen or bone 
marrow cells from immunocompetent  mice (3, 5, 16). Clear- 
ance of the organisms from infected lungs is completed in 
the majority of animals by 19 d after reconstitution of spleen 
cells (3, 5). Findings presented in this report show that en- 
dogenous I1:1 is essential for resistance to P. carinii infection 
in this host. 
Materials and Methods 
Mice.  6-8-wk-old  C.B-17 +/+ and C.B-17 scid/scid mice  were 
obtained from the Trudeau Animal Breeding Facility A founda- 
tion stock of  SCID mice  was originally  obtained  from Dr. Leonard 
Schultz of The Jackson Laboratory (Bar Harbor, ME). They 
were bred and housed  in microisolator  cages  containing sterilized 
food and water, and were shown to be free of most common 
pathogens (3). 
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infection in mouse lung was determined by counting the number 
ofP. carinii  nuclei as described previously (3, 17). In brief, the lungs 
were pushed through a stainless  steel  screen  into HBSS (Gibco 
Laboratories, Grand Island, NY), and the resulting suspension was 
diluted for making cytocentrifuge prepared smears. The smears were 
stained with Diff-Quik (Baxter, Miami, FL), and the number of 
P. carinii nuclei per 10-30 oil immersion fields was counted. This 
number was used to calculate total P. carinii nuclei per lung. With 
this method, 103  '~ nuclei per lung represented  the detection limit. 
The mean percent variance among counts done by individual in- 
vestigators was 11% (3).  All counts done within an experiment 
were conducted by a single investigator without knowledge of the 
origin of the slides. 
Reconstitution of SCID Mice with Immunocompetent Spleen Cells. 
Spleens were collected aseptically from 6-8-wk-old C.B.-17  +/+ 
mice, diced into small pieces, gently pushed through a stainless 
steal screen into HBSS, and triturated with a Pasteur pipette. After 
removal of debris, the cells were washed twice with PBS (pH 7.2), 
counted, and resuspended in PBS at a concentration of 5  x  107 
nucleated cells per ml. Recipient SCID mice were given 1 ml of 
the cell suspension  by injection into a tail vein. 
Kinetics of ILl Production in Reconstituted SCID Mice.  Groups 
of four reconstituted SCID mice were killed at the time of recon- 
stitution (0 d postreconstitution [DPK 0]) I, or at predesignated 
time points as indicated in Fig. 1 A. In addition, four P. carinii-free 
unreconstituted SCID mice were killed to determine baseline Ibl 
production. The mice were anesthetized, bled by cardiac puncture, 
and the serum collected. After the bleeding, mice were killed and 
the lungs were removed and processed  for enumeration P. carinii 
nuclei and Ibl assay. Sera and lung suspensions  for Ibl assay were 
stored at  -70~  until use. Sera from mice killed at the same time 
point were pooled and diluted 1:8 with RPMI 1640 (Gibco Labora- 
tories) before use. Lung suspensions  were thawed, homogenized 
with a motorized Teflon pestle, and centrifuged at 10,000 g at 4~ 
for 30 min. The supernatant was carefully decanted and sterilized 
by filtration (0.22-#m pore-size filter)  before being assayed. 
11.,1 Assay.  The amount of Ibl (U) in the lungs and serum 
was determined by the murine D10.N4.M cell proliferation assay 
(18). The IL-1 titre was defined as the reciprocal of the highest di- 
lution of test sample  that produced a half-maximal proliferative 
response of D10.N4.M cells. The detection limit of the assay was 
20 U per ml for the serum and 100 U per lung. Selected samples 
were also assayed for IL-1 activity in the presence of different con- 
centrations  of 35F5  to  assure  the  specificity  of assay. A  dose- 
dependent inhibition of D10.N4.M ceil proliferation was noted (data 
not shown). 
Treatment of Reconstituted SCID Mice with 35F5 mA h  The 35F5 
was generated and purified from serum-free hybridoma call culture 
supernatants by protein G affinity chromatography (13). Detailed 
descriptions of 35F5 mAb and its activities in vivo and in vitro 
have been reported previously (10, 11, 13-15). Recipient mice were 
given intraperitoneal injections of 200 #g of pure 35F5 or control 
rat IgG (Sigma Chemical Co., St. Louis, MO) in 0.2 ml of pyrogen- 
free saline. This dose of 35F5 was based  on that used in murine 
models of acute listeriosis  (10) and turpentine-induced sterile ab- 
scess (14). The number of animals used and regimes of those treat- 
ments are detailed in Table 1. All mice were killed at DPK 19 and 
the numbers of P. carinii nuclei in their lungs were determined. 
In an additional experiment, groups of four reconstituted SCID 
mice receiving 200/~g of either 35F5 or rat control IgG at DPR 
2 and 8 were killed at the predetermined time points as shown 
(see Fig.  2). The lungs were lavaged (19) before being processed 
for R carinii  nuclear counts. Performance of such lavage in R carinii- 
infected mice does not markedly alter the number ofP. carinii nuclei 
per lung (unpublished data). Total lavage cell numbers were counted 
in a hemacytometer, and differential cell counts were done by ex- 
amination of ceU smears produced with a cytocentrifuge and stained 
with Diff-Quik. The lavage ceils were also stained  with FITC- 
conjugated F(ab')z fragments of anti-Thy-l.2, -CD4,  -CD8,  and 
-Ig for analysis of lymphocyte phenotypes by using a FACScan  | 
cytofluorometer (Becton Dickinson & Co., Sunnyvale,  CA) (3). 
StatisticalAnalysis.  Data are presented as means _+ SEM of  results 
calculated from four animals. Differences in the observations made 
between the groups of mice treated with 35F5 and rat control IgG 
were analyzed using Mann-Whitney U  test (20).  The difference 
was considered significant  if p  <0.05. 
Results and Discussion 
Effect of Type I ILIR Blockade on the Clearance of P. carinii 
from Lungs.  To acquire evidence that endogenous ID1 is re- 
quired for P. carinii clearance in reconstituted SCID mice, these 
mice were treated with 35F5  or rat  IgG as control.  Table 
1 shows the numbers of P. carinii nuclei in the lungs of un- 
reconstituted control SCID mice and reconstituted SCID mice 
treated with  35F5  mAb  or control rat  IgG.  In agreement 
with our previous studies (3, 5), aU unreconstituted SCID 
mice had substantial numbers ofP. carinii in their lungs when 
they were killed (about 9-wk-old), whereas reconstituted SCID 
mice had cleared P. carinii by DPR 19. Intraperitoneal injec- 
tion of 35F5  into reconstituted SCID  mice on DPR 2,  8, 
and 12 almost completely inhibited the clearance ofP. carinii 
seen on DPR  19 in reconstituted SCID  mice that  had re- 
ceived control rat  IgG (p <0.05,  Table 1).  We then deter- 
mined when endogenous IL-1 was required for the clearance 
Table  1.  Effect of 35F5  Treatment on P. carinii clearance  from 
the Lungs  of SCID Mice 19 d after Reconstitution with 
Immunocompetent Spleen Cells 
No.  of 
P. carinii 
Spleen  cell  Antibody  Treatment time  nuclei/lung 
reconstitution  treatments  (DPR)  (logto) 
No  No  -  7.00  _+ 0.11 
Yes  No  -  <3.98  _+ 0.00 
Yes  Rat  IgG  2,8,12  <3.98  _+ 0.00 
Yes  35F5  2,8,12  6.31  _+ 0.15" 
Yes  35F5  2  5.77  _+ 0.65" 
Yes  35F5  8  <3.98  _+ 0.00 
Yes  35F5  12  <3.98  _+ 0.00 
1 Abbreviation used in this paper: DPR, days postreconstitution.  " p <0.05  versus group treated with rat IgG. 
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seen in mice treated with 35F5 on DPK 2 (p <0.05,  Table 
1), however, a single injection of 35F5 on either DPK 8 or 
12 had no significant effect on the clearance.  These results 
indicate that for clearance ofP. carinii in SCID mice, endoge- 
nous 1I.-1 is required mainly in the early stage of the immune 
response induced by the reconstitution. The inhibition of clear- 
ance was not due to depletion of lymphocytes (particularly 
CD4 + cells) by 35F5, because it was previously determined 
that treatment of normal or Listeria-infected  mice with the 
amount  of 35F5  used in  the current  experiments  did not 
significantly  change the numbers of splenic Tby 1.2 +, CD4 +, 
CD8 +,  or Ig + cells  (10). 
Kinetics of lL.1 Production in Reconstituted SCID Mice  The 
inhibition ofP. carinii clearance from the lungs of reconstituted 
SCID mice by treatment  with 35F5 but not control IgG, 
suggests the importance of endogenous I1-1 in resistance to 
P. carinii.  It was therefore considered important to determine 
whether there is an association between resistance to P. carinii 
and local and/or systemic production of I1.-1. Fig. 1 A  shows 
I1-1 activity in SCID mice that were either free of P. carinii 
or infected with P. carinii,  and that  either had or had not 
been reconstituted with immunocompetent spleen cells. The 
amount of I1.1  in the lungs of P. carinii-free mice was 519 
_+  135 U/lung,  whereas P. carinii-infected  SCID mice had 
6,719  +  3,677 U/lung at the time ofreconstitution. Recon- 
stitution ofP. carinii-infected SCID mice significantly  increased 
the local production oflbl that peaked on DPK 7 at 68,268 
+_ 21,717 U/lung and remained at about this level until DPK 
12 (Fig.  1 A). The amount of I1-1 then declined rapidly at 
the end of the experiment (DPK 19), when the infection was 
cleared,  to  a  level  comparable  with  that  in  the  lungs  of 
P. carinii-ffee SCID mice. No I1-1 activity (<20 U/ml) was 
detected in the serum of any animals,  regardless of their status 
of infection or immunocompetence (data not shown).  The 
appearance and maintenance of high I1-1 levels in the lungs 
of reconstituted SCID mice and its rapid decrease in concor- 
dance with P. carinii clearance, suggests that this cytokine may 
participate  in host defenses against P.  carinii. 
To examine whether 35F5 treatment  altered production 
of Ibl, the IIA levels in the lungs of 35F5-treated mice were 
also determined and compared with those from control IgG- 
treated animals. In Fig. 1 B, it can be seen that the amounts 
of II.-1 in the lungs of mice treated with either 35F5 or con- 
trol rat IgG were similar at the time of reconstitution (DPR 
0) and on DPR 3.  After DPR 3,  35F5 treatment  did not 
change the kinetics of IL-1 production, despite the fact that 
measurable Ibl levels were slightly lower in the lungs of 35F5- 
treated mice as compared with control IgG-treated mice. Al- 
though these results might be predictable,  there are certain 
technical problems that  could interfere with the Ibl  assay 
employed. Rather than by binding directly to, and neutralizing 
IL-1, 35F5 mAb inhibits Ibl action by binding to II.,1 type 
I receptors, and prevents II.-1 binding to its cellular receptors 
(13).  The only assays available  to us for murine  IL-lo~ and 
I1.1~/is either an Ibl-dependent cell proliferation assay (used 
in the present study), or an IL-1 competitive inhibition binding 
assay (10).  Because both these assays require direct binding 
of Ibl in samples to II.-1 receptors on cells, any residual 35F5 
mAb in the samples derived from 35F5-treated mice could 
possibly interfere with the II.-1 assays. Therefore, certain cau- 
tions should be taken in the interpretation  of these results. 
35F5 mAb  Treatment Inkibits Recruitment  of Inflammatory 
Cells into the Lungs.  The finding that 35F5 treatment was 
effective only if given well before P. carinii were cleared from 
the lungs (Table 1), and that  a substantial  time lag existed 
between the local appearance of peak Ibl activity and P. carinii 
clearance (Fig.  1 A), suggested that I1.-1 functions by mecha- 
nisms other than a direct effect on P. carinii.  II.-1 elicits local 
accumulation and activation of inflammatory cells (8, 11, 21). 
These cells are considered important in host defenses against 
P.  carinii  (3,  4,  6,  22-26)  and,  indeed,  reconstitution  of 
P. carinii-infected SCID mice with immunocompetent spleen 
cells induces significant recruitment of inflammatory cells into 
bronchoalveolar lumina (3, 5). The effect of 35F5 treatment 
on pulmonary inflammation in reconstituted SCID mice was 
therefore investigated.  At DPR 2, there was no significant 
difference in the composition of cell populations in bronchoal- 
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Figure 1.  (A) Kinetics of the clearance of P. carinii (B) and production of Ibl (D) in the lungs of SCID mice reconstituted with immunocompetent 
spleen cells. (Bar) IL-1 activity in the lungs of P. carinii-free SCID mice. (B) Measurable IIr  levels in the lungs of reconstituted SCID mice treated 
with either 35F5 mAb (Q) or control of rat IgG (O). 
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Figure 2.  Effect of 35F5 treatment on composition of 
cell populations in the bronchoalveolar hvage fluids  of 
SCID mice reconstituted with immunocompetent spleen 
cells. (Ill) 35FS-treated mice and ([~) rat control IgG- 
treated mice. (A) Time points when 35F5 or rat IgG was 
administered. (*)p <0.05 versus rat IgG treated control 
mice.  (* *)p <0.01 versus rat IgG treated control mice. 
veolar lavage fluids of mice treated with 35F5 or rat IgG (Fig. 
2). After DPR 2, the numbers of macrophages, neutrophils, 
and lymphocytes in the lavage fluids of control mice increased 
consistently  and significantly, whereas pulmonary recruitment 
of all types of cells examined was markedly inhibited by 35F5 
treatment  (Fig.  2).  The most  striking effect of 35F5  treat- 
ment was on the inhibition  of neutrophil recruitment  that 
was first evident by DPR  5  and reached  maximum  inhibi- 
Figure 3.  Bronchoalveolar lavage cells from a reconstituted SCID mouse treated with 35F5 (A) or rat lgG (B) on DPR 2 and 8 and killed on DPR 
12. In addition to many neutrophils, the bronchoalveolar lavage fluid of the control mouse (B) contains larger macrophages with basophilic cytoplasm 
than are found in the 35FS-treated animal (A).  (x360). 
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fluids of control mice was nearly 30 times that of 35F5-treated 
mice (Fig.  2). Although the inhibitory effect of 35F5 treat- 
ment on macrophage recruitment was not as dramatic as that 
on neutrophils, macrophages from control mice nevertheless 
had a more activated appearance than those from 35F5-treated 
animals (Fig. 3). Treatment with 35F5 also markedly reduced 
the number of lymphocytes accumulating in the bronchoal- 
veolar lumina. However, flow cytofluorometric analysis of 
these cells showed no selective reduction of cells with regard 
to phenotype (Thy 1.2 + , CD4 +  , CD8 + , or Ig +) (data not 
shown). These findings suggest that 35F5 may inhibit the 
clearance of P. carinii from the lungs of reconstituted SCID 
mice by blocking IL,  l-dependent inflammatory responses. 
Based on the results presented in this paper, we conclude 
that IL-1 is important in host defenses against P. carinii in 
the SCID mouse model. It is possible that reduced numbers 
of CD4 + cells may underlie an impaired capacity to induce 
IL-1 production, thus accounting for the high incidence of 
P. carinii infection seen in AIDS patients (1). In view of ear- 
lier results irnplicating TNF-c~ (5) as a mediator in host defenses 
against P. carinii,  the demonstration that II.-1 is also an im- 
portant mediator shows that the host defenses against P. carinii 
probably result from combined effects of several cytokines. 
This conclusion is in accordance with the findings that nei- 
ther blockade of IL-1 activity (Table 1) nor neutralization of 
TNF-ot activity (5) could completdy inhibit the dearance 
ofP. carinii. It will be worthwhile to investigate whether Ibl 
treatment is of practical therapeutic benefit in human P. carinii 
pneumonia. In addition, the results reported here provide the 
first in vivo evidence that II.-1 is important in resistance  to 
a protozoan infection. 
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